John M. Pagel, MD, PhD, highlights the role of current targeted therapy options, including BTK and BCL2 inhibitors, as treatment for frontline chronic lymphocytic leukemia and discusses considerations that may impact treatment selection.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть